BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer

EGFR mutation-positive NSCLC tumors are highly heterogeneous, therefore, exploring an agent simultaneously targeting multiple EGFR mutations may be valuable for clinical practice. Compared with osimertinib, BEBT-109 shows more sensitive and extensive antitumor activity in EGFR mutant NSCLC, while sp...

Full description

Bibliographic Details
Main Authors: Fushun Fan, Minhua Zhou, Xiaolan Ye, Zhenxian Mo, Yaru Ma, Liying Luo, Xiaotong Liang, Haiqi Liu, Yunwo Weng, Mingsheng Lin, Xinjian Liu, Xiong Cai, Changgeng Qian
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Translational Oncology
Subjects:
BEBT-109
T790M
exon20ins
G719S
Pan-mutant-selective EGFR inhibitor
NSCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320304538

Internet

http://www.sciencedirect.com/science/article/pii/S1936523320304538

Similar Items